124 288

Cited 11 times in

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.

Authors
Jin, YJ; Lee, JW; Lee, JI; Park, SH; Park, CK; Kim, YS; Jeong, SH; Kim, JH; Hwang, SG; Rim, KS; Yim, HJ; Cheong, JY; Cho, SW; Lee, JS; Park, YM; Jang, JW; Lee, CK; Sohn, JH; Yang, JM; Han, S
Citation
BMC gastroenterology, 13:74-74, 2013
Journal Title
BMC gastroenterology
ISSN
1471-230X
Abstract
BACKGROUND: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).



METHODS: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes.



RESULTS: Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7 × 10(5) and >7 × 10(5)), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.



CONCLUSIONS: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.
MeSH terms
Antiviral Agents/adverse effects/*therapeutic useDrug Therapy, CombinationFemaleHepacivirus/geneticsHepatitis C, Chronic/*drug therapy/virologyHumansInterferon-alpha/adverse effects/*therapeutic useMaleMiddle AgedPolyethylene Glycols/adverse effects/*therapeutic useRecombinant Proteins/adverse effects/therapeutic useRepublic of KoreaRetrospective StudiesRibavirin/therapeutic useViral Load
DOI
10.1186/1471-230X-13-74
PMID
23627926
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
정, 재연조, 성원
Full Text Link
Files in This Item:
23627926.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse